Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Valuation hits a ten-year low! Barclays initiates coverage on 26 US medical technology stocks, with Stryker (SYK.US) among its top picks

Valuation hits a ten-year low! Barclays initiates coverage on 26 US medical technology stocks, with Stryker (SYK.US) among its top picks

智通财经智通财经2026/10/08 06:23
Show original

Barclays analyst Christopher Pasquale on Tuesday initiated coverage on 26 US-listed medtech companies for the first time, and included Stryker (SYK.US) and Abbott (ABT.US) on the recommended list of large-cap medtech stocks.

According to Zhihu Finance APP, Barclays analyst Christopher Pasquale on Tuesday initiated coverage of 26 U.S.-listed medical technology companies for the first time, placing Stryker (SYK.US) and Abbott (ABT.US) on the recommended list of large-cap medical technology stocks. The bank noted that the recent underperformance of the medical technology sector provides investors with an opportunity to buy high-quality companies at attractive valuations.

Before Pasquale voiced his optimistic outlook, the sector benchmark iShares U.S. Medical Devices ETF (IHI.US) had fallen nearly 19% over the past five years, while the S&P 500 Index rose nearly 77% over the same period.

In his report, he wrote: “After several years of relative underperformance due to slowing revenue growth, medical technology stocks are now trading at their lowest valuations in a decade, and at the deepest discount to the S&P 500 Index since the peak of the tech bubble.”

He described the current sell-off as an overreaction, partly due to multiple company-specific headwinds over the past year, “making the industry’s return to average growth rates appear as if fundamentals have deteriorated more significantly.”

Pasquale expects that a potential stabilization in large-cap medical technology companies’ revenues next year could serve as a catalyst to boost market sentiment and valuation multiples. “While we believe investors should remain cautious until the outlook becomes clearer, we are convinced that the current market environment offers quite attractive investment opportunities,” he added.

Which stocks are worth buying? Stryker and Edwards Lifesciences top the overweight list

Barclays named Stryker and Edwards Lifesciences (EW.US) as their top large-cap picks, with target prices of $375 and $110, respectively. Other large-caps rated as “Overweight” include Abbott, with a target price of $120; GE HealthCare Technologies (GEHC.US), with a target price of $85; and Intuitive Surgical (ISRG.US), with a target price of $485.

For small and mid-cap stocks, Barclays singled out Beta Bionics (BBNX.US), Dexcom (DXCM.US), and LivaNova (LIVN.US) as their top picks, with target prices of $30, $115, and $105, respectively. Other small and mid-cap medical technology stocks rated as “Overweight” include Axogen (AXGN.US), with a target price of $55; Bausch + Lomb (BLCO.US), with a target price of $24; Procept BioRobotics (PRCT.US), with a target price of $30; and TransMedics (TMDX.US), with a target price of $120.

Which stocks require caution? Medtronic and Boston Scientific rated “Neutral”; Baxter and Becton Dickinson downgraded

Companies rated as “Neutral” include: Alcon (ALC.US), target price $70; Averitas Technologies (AVR.US), target price $10; Boston Scientific (BSX.US), target price $48; Humacyte (HUMA.US), target price $0.50; Insulet (PODD.US), target price $150; Medtronic (MDT.US), target price $95; Minimed (MMED.US), target price $22; Senseonics (SENS.US), target price $10; Tandem Diabetes (TNDM.US), target price $18; Cooper Companies (COO.US), target price $60; Zimmer Biomet (ZBH.US), target price $100.

Companies rated as “Underweight” include: Baxter International (BAX.US), target price $20; Becton Dickinson (BDX.US), target price $165; Inspire Medical (INSP.US), target price $65.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Citigroup raises profit forecast; Australian exchange operator's stock price rises

On Thursday, shares of Australian Securities Exchange operator ASX Ltd (ASX.AX) surged to nearly a two-month high after Citi raised its annual profit outlook for the company, citing a strong first-quarter performance and predicting robust market activity to continue into the first half of the year. Details are as follows: The exchange operator's average daily trading volume in the spot market rose 16% year-on-year in September. Citi analysts noted that daily futures trading volumes climbed 44% during the month, approaching historical highs, possibly reflecting structural and cyclical factors, including interest rate prospects and changes in the bond market. Citi added that strong market activity is expected to last at least through the first half, and consequently raised ASX's annual earnings-per-share forecast by 2%. Citi pointed out, however, that corporate market activity remained subdued in September. Short-term market activity is expected to be boosted with Glencore's GLEN.L company planning a secondary listing in October and Firmus company planning an initial public offering (IPO) in October. Both Citi and UBS raised their target price for ASX from AU$60.10 and AU$64.20 to AU$61.00 and AU$65.50, respectively. Meanwhile, Goldman Sachs remains cautious about the strategy of the new CEO, Anthony Attia, and the company's potential future financial situation. Goldman Sachs is also alert to execution risks in the exchange operator's CHESS system replacement and technology modernization plans. This comes after the central bank stated in September that the company's clearing and settlement facilities had not met the bank's expectations. ASX shares closed up 3.8%, reaching their highest level in nearly two months and ranking among the top performers on the S&P/ASX 200 index.

路透社•2026/10/08 06:11

Updated version 2 – Reports indicate that Firmus is considering adjustments to its $5 billion IPO plan, causing the stock price of Australia’s Maas Group to plunge.

Code for media reports has been modified; analyst comments have been added in points 4 and 5, and the closing share price has been updated. Kumar Tanishk/Aamir Khalid, Reuters, October 8 – On Thursday, Maas Group (MGH.AX), an Australian construction services provider, saw its share price plunge 30%, marking the biggest intraday drop on record. This followed reports that Firmus, an AI company backed by Nvidia (NVDA.O), was considering changing the terms of its highly anticipated 5.0 billions USD initial public offering (IPO). The stock at one point fell to a low of AUD 4.47, its lowest level since May 6, and ended the session down 22.4%. The company’s market capitalization evaporated by about AUD 517 millions (359.52 millions USD). More details: - Maas holds a 3.2% stake in this data center operator, after injecting an additional AUD 300 millions by subscribing for ordinary and preferred shares at AUD 230 per share in early August (link). - Maas stated in exchange filings that speculation on whether the IPO would proceed as scheduled had put pressure on market sentiment, adding that the company was unaware of any undisclosed information that could explain the transaction. - Firmus counts OpenAI as a key customer and is preparing for what would be the second-largest IPO in Australian history (link). Earlier this week, reports emerged that Firmus might cut its offering price from AUD 11 per share. - “This sell-off reflects a rational downward adjustment of the intrinsic value of Maas’ holding in Firmus, but the scale of the drop seems overdone,” said Emanuel Ajay Datt, Managing Director at Datt Group. - Datt said if Firmus reduced its offering price from AUD 11 to AUD 9 per share, the value of Maas’ holding would fall by about AUD 75 millions, but he added that this loss was limited compared with the day’s drop in the company’s market capitalization. - If the listing succeeds, it will mark the largest IPO in Australia in nearly thirty years, second only to the almost 10 billions AUD public offering of Telstra’s TLS.AX unit in 1997, Australia’s top telecom operator. - Prior to Thursday’s share crash, Maas Group’s share price had risen about 44% over the past 12 months, as investors were optimistic about its links to AI-driven data center construction projects. - Firmus has not yet responded to Reuters’ request for comment. (1 USD = 1.4380 AUD) (For the convenience of non-native English speakers, Reuters automatically translates its articles into several other languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of the translated text and provides them solely for readers' convenience. Reuters assumes no responsibility for any damages or losses arising from the use of automated translations.)

路透社•2026/10/08 06:06

TSMC September sales reached 511.86 billions New Taiwan dollars, up 54.6% year-on-year.

Compared to August 2026, revenue declined slightly by 0.6%. Taking a longer-term view, TSMC's overall revenue performance in the first three quarters of 2026 has been impressive. From January to September 2026, the company’s accumulated revenue reached TWD 3,898.727 billions, achieving a significant increase of over 40% compared to the same period last year.

华尔街见闻•2026/10/08 05:57

In September, Japanese investors withdrew from foreign bond markets for the second consecutive month.

Reuters, October 8 – In September, Japanese investors became net sellers of foreign bonds for the second consecutive month, driven by rising borrowing costs in the US and Europe, as well as increasingly attractive domestic yields that prompted them to withdraw from overseas bond markets. Data released by Japan's Ministry of Finance on Tuesday showed that Japanese investors were net sellers of 969 billion yen ($613 million) in foreign bonds last month, which was lower than the previous month's net sales of 1.16 trillion yen. They net sold 1.43 trillion yen in long-term foreign currency bonds—a six-month high—while purchasing about 457 billion yen in short-term notes. The increase in Japanese interest rates is beginning to attract some of the country's vast overseas investments back home, marking a significant shift in global capital flows. Year to date, Japanese investors have net sold about 5.08 trillion yen in foreign bonds, the highest since 2022. This capital outflow could support the yen’s exchange rate and put pressure on bond markets that have long considered Japan a major buyer. Soaring energy costs have heightened inflation concerns, prompting the Federal Reserve (FED) and the European Central Bank to raise interest rates in September, which has further pressured global bond markets. Earlier this week, Japan's benchmark 10-year government bond yield rose to 3.122%, its highest in 30 years, increasing the appeal of domestic bonds. In September, led by the Bank of Japan, Japanese institutions sold a net 2.49 trillion yen in long-term foreign bonds, a seven-month high. Life insurance companies and investment trust managers also recorded net sales of 288.6 billion yen and 200.1 billion yen respectively. However, trust accounts net purchased 1.2 trillion yen in long-term foreign currency bonds, highlighting divergent investment strategies among Japanese institutional investors. Another Bank of Japan report showed that in the first eight months of this year, Japanese investors net sold 4.74 trillion yen in US Treasuries, while net purchasing 355.85 billion yen in European bonds. Within Europe, Japanese investors net bought 329.82 billion yen in Italian bonds, while net selling 208.59 billion yen and 94.25 billion yen in French and German bonds, respectively. (1 US dollar = 158.1400 yen)

路透社•2026/10/08 05:26
In September, Japanese investors withdrew from foreign bond markets for the second consecutive month.